Comparative Pharmacology
Head-to-head clinical analysis: LEVLITE versus TRI MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVLITE versus TRI MILI.
LEVLITE vs TRI-MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a progestin that suppresses ovulation by inhibiting gonadotropin release (LH and FSH) and alters cervical mucus, endometrial thickness, and tubal motility.
TRI-MILI is a combination of norethindrone (a progestin) and ethinyl estradiol (an estrogen). Norethindrone suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol stabilizes the endometrium and potentiates the progestational effects.
One tablet (levonorgestrel 0.1 mg, ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets.
For mild-to-moderate hypertension: 1 tablet (containing triamterene 50 mg and hydrochlorothiazide 25 mg) orally once daily. May increase to 2 tablets daily if needed. Maximum dose: 4 tablets daily.
None Documented
None Documented
Terminal elimination half-life: 21-28 hours; clinical context: permits once-daily dosing
Terminal elimination half-life is 6-9 hours in adults with normal renal function, allowing twice-daily dosing; prolonged in renal impairment.
Renal: ~50% (30% as unchanged drug, 20% as metabolites); Fecal: ~40%; Biliary: minor
Renal excretion of unchanged drug accounts for 60-80% of elimination; biliary/fecal excretion accounts for 15-25%; remainder metabolized.
Category C
Category C
Oral Contraceptive
Oral Contraceptive